Purple Biotech Ltd (PPBT)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
Working costs have been on the rise at the company in the fiscal period closing December 31 2022
company reported fourth quarter of 2022 operating deficit of $-22.603 million
Published Mar 23 2023
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
The stockholders did not expect any adjustments at the business during the the October to December 31 2022 reporting cycle at the PPBT. But, they monitor the company's operating deficit that was at $-22.603 million, during the same period. The operating deficit has contracted from $-17.934 million, from the fourth quarter of 2021. But more crucially, the analysts are guessing, if the Purple Biotech Ltd s' will start to report the revenue.
It was a good financial reporting period for the entity, although the company has not clinched any revenues so far. So in what way we should measure, if it was an encouraging quarter, the net profits surged from $18.468 million in the a year ago, to $21.760 million, in the fiscal period closing December 31 2022.
PPBT reported shortfall of $21.76 million and revenue of $0.00 million in the fiscal period 2022.
The Major Pharmaceutical Preparations company reported further 0 compared to $0.00 in the previous fiscal year, while by 0 % from $0.00 million a year ago.
Purple Biotech Ltd is expected to report next financial recent numbers on March 02, 2024.